SCHEMBL4267388

SCHEMBL4267388

N#Cc1c(Cl)ncnc1Nc1ccccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.53
KDM4E B2RXH2 2/20 0.53
HSD17B10 Q99714 1/20 0.53
TTBK1 Q5TCY1 1/20 0.50
TTBK2 Q6IQ55 1/20 0.50
EGFR P00533 2/20 0.47
BTK Q06187 1/20 0.46
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
CACNA1B Q00975 1/20 0.45
APBA1 Q02410 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
FLT3 P36888 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.42
IGF1R P08069 1/20 0.41
TP53 P04637 1/20 0.41
ERBB2 P04626 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4261576 0.83 ADRA2A (0.41) TSHRKDM4EHSD17B10EGFRERBB2
SCHEMBL4266699 0.82 SRC (0.48) TSHRKDM4EHSD17B10EGFRMAPK1
SCHEMBL4268138 0.80 DYRK1A (0.43) TSHRKDM4EHSD17B10EGFRMAPT
SCHEMBL4259860 0.77 LCK (0.44) TSHRKDM4EHSD17B10MAPTBCL6
SCHEMBL4266486 0.77 SRC (0.57) BTKCLK1SRC
SCHEMBL839219 0.76 TTBK1 (0.57) TSHRKDM4ETTBK1TTBK2EGFR
SCHEMBL23162568 0.75 LMNA (0.52) TSHRKDM4EHSD17B10MAPTMAPK1
SCHEMBL29623213 0.75 LMNA (0.52) TSHRKDM4EHSD17B10MAPTMAPK1
SCHEMBL4269335 0.73 EGFR (0.52) KDM4EEGFRL3MBTL1ALDH1A1HPGD
SCHEMBL4264958 0.73 KDR (0.54) TTBK1TTBK2EGFRMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579356-B2 Thia-tetraazaacenaphthylene kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2009-08-25 US disclosed
US-20070265264-A1 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-15 US disclosed
WO-2006118749-A1 THIA-TETRAAZAACENAPHTHYLENE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265264-A1 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide ADK, MAP3K9, MAP4K5 TSHR 2984/4885KDM4E 1228/4885HSD17B10 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.